← All trials
NCT00157079
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2002
- Primary completion
- —
- Completion date
- Dec 1, 2003
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- BaxaltaLead sponsor
- Allergy, Asthma & Immunology Assoc., Omaha, NEOverall official - principal investigator
- First Allergy and Clinical Research Center, Engelwood, COOverall official - principal investigator
- Asthma and Allergy Center, Papillion, NEOverall official - principal investigator
- University of South FloridaOverall official - principal investigator
- Pediatric Allergy/Immunology Associates, Dallas, TXOverall official - principal investigator
- Allergy Associates of the Palm Beaches, North Palm Beach, FLOverall official - principal investigator
- Rush UniversityOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.